Ruxolitinib cream improves sleep disturbances, itch in children with atopic dermatitis
SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting. As Healio previously reported, ruxolitinib cream, a topically administered selective Janus kinase 1 and 2 inhibitor, has proven to be an effective